C H Ohlmann

Summary

Country: Germany

Publications

  1. doi request reprint [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Homburg Saar, Deutschland
    Urologe A 47:1218-23. 2008
  2. doi request reprint [Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstr, 66421, Homburg Saar, Deutschland
    Urologe A 55:1164-72. 2016
  3. doi request reprint [PREFERE - Study on the rise]
    Carsten H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstr, 66421, Homburg Saar, Deutschland
    Urologe A 55:313-7. 2016
  4. doi request reprint [Chemotherapy of prostate cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitat des Saarlandes, Kirrbergerstr, 66421, Homburg Saar, Deutschland
    Urologe A 54:1461-9; quiz 1470. 2015
  5. doi request reprint [Metastasized prostate cancer. Position paper on the use of chemotherapy]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Kirrbergerstraße 1, 66424, Homburg, Deutschland
    Urologe A 54:998-1001. 2015
  6. doi request reprint [Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrberger Strase, 66424, Homburg Saar, Deutschland
    Urologe A 52:1534-8, 1540. 2013
  7. doi request reprint [Bone metastases]
    C H Ohlmann
    Leitender Oberarzt Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstr 1, Gebäude 6, 66421 Homburg Saar
    Aktuelle Urol 44:141-9. 2013
  8. doi request reprint Novel options for the treatment of castration-resistant prostate cancer
    Carsten H Ohlmann
    Department of Urology, Saarland University, Kirrbergerstrasse 1, Homburg Saar, Germany
    World J Urol 30:495-503. 2012
  9. doi request reprint [Third generation anti-androgen therapy of advanced prostate cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstraße 1, Gebäude 6, 66421, Homburg Saar, Deutschland
    Urologe A 51:522-6. 2012
  10. doi request reprint Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer
    Carsten Henning Ohlmann
    Division of Urologic Oncology, Department of Urology, University of Cologne, Cologne, Germany
    Urol Oncol 29:664-9. 2011

Detail Information

Publications23

  1. doi request reprint [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Homburg Saar, Deutschland
    Urologe A 47:1218-23. 2008
    ..Based on the expression profile, an individual treatment strategy can be applied to each patient. Further clinical studies should determine the clinical efficacy of molecular targeted therapy in patients with AIPC...
  2. doi request reprint [Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstr, 66421, Homburg Saar, Deutschland
    Urologe A 55:1164-72. 2016
    ..The addition of a cytotoxic chemotherapy was unable to provide a survival benefit over castration alone in several clinical trials using different chemotherapy regimens...
  3. doi request reprint [PREFERE - Study on the rise]
    Carsten H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstr, 66421, Homburg Saar, Deutschland
    Urologe A 55:313-7. 2016
    ..With the increased recruitment numbers, it seems realistic that the required milestones in recruiting will be achieved...
  4. doi request reprint [Chemotherapy of prostate cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitat des Saarlandes, Kirrbergerstr, 66421, Homburg Saar, Deutschland
    Urologe A 54:1461-9; quiz 1470. 2015
    ..In addition, docetaxel and cabazitaxel now represent the standard for first and second line therapy in patients with castration-resistant prostate cancer. ..
  5. doi request reprint [Metastasized prostate cancer. Position paper on the use of chemotherapy]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Kirrbergerstraße 1, 66424, Homburg, Deutschland
    Urologe A 54:998-1001. 2015
    ..Because no comparative studies are available, especially for castration-resistant prostate cancer (mCRCP), it remains unclear which patients will profit best from which therapy...
  6. doi request reprint [Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrberger Strase, 66424, Homburg Saar, Deutschland
    Urologe A 52:1534-8, 1540. 2013
    ..If neoadjuvant chemotherapy has not been used and patients are fit enough to receive cisplatin, adjuvant chemotherapy should be considered in patients with pT3-pT4 and/or lymph node metastases. ..
  7. doi request reprint [Bone metastases]
    C H Ohlmann
    Leitender Oberarzt Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstr 1, Gebäude 6, 66421 Homburg Saar
    Aktuelle Urol 44:141-9. 2013
    ..In case of accompanying neurologic symptoms immediate intervention and decompression of the neural structures is warranted in order to prevent irreversible neurologic deficits...
  8. doi request reprint Novel options for the treatment of castration-resistant prostate cancer
    Carsten H Ohlmann
    Department of Urology, Saarland University, Kirrbergerstrasse 1, Homburg Saar, Germany
    World J Urol 30:495-503. 2012
    ..Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials...
  9. doi request reprint [Third generation anti-androgen therapy of advanced prostate cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstraße 1, Gebäude 6, 66421, Homburg Saar, Deutschland
    Urologe A 51:522-6. 2012
    ..Altogether, the development of new antihormonal therapies is a considerable expansion of the therapy options for patients which could contribute to an improvement of the quality of life and the prognosis of patients...
  10. doi request reprint Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer
    Carsten Henning Ohlmann
    Division of Urologic Oncology, Department of Urology, University of Cologne, Cologne, Germany
    Urol Oncol 29:664-9. 2011
    ....
  11. doi request reprint [When should systemic chemotherapy be used for urinary bladder carcinoma?]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstraße 1, 66421 Homburg Saar, Deutschland
    Urologe A 51:325-30. 2012
    ..Vinflunin has become the standard therapy in second-line treatment and should represent the comparator for further clinical trials in this setting...
  12. doi request reprint [Resection of metastases from prostate cancer]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstraße 1, Gebäude 6, 66421 Homburg Saar, Deutschland
    Urologe A 51:363-7. 2012
    ..Here, the available data covering the different clinical scenarios for the resection of metastases in prostate cancer and recommendations of recently published guidelines are reviewed...
  13. doi request reprint [Prognostic factors for survival of patients with metastatic renal cell carcinoma]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstrasse 1, 66482, Homburg Saar, Deutschland
    Urologe A 48:625-7. 2009
    ..The present article reviews the development of the prognostic models and their use in recent clinical trials. Furthermore, a reasonable algorithm for the treatment of patients with metastatic RCC is presented...
  14. doi request reprint [Diagnostic work-up and treatment of bladder cancer: current developments]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstrasse 1, 66421 Homburg Saar
    Urologe A 49:172-7. 2010
    ..This article critically reviews the emergent developments of the last 12-15 months and comments on their clinical efficacy for the treatment of bladder carcinoma...
  15. doi request reprint [What comes after docetaxel?]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstrasse 1, 66421, Homburg Saar, Deutschland
    Urologe A 49:64-8. 2010
    ..This review focuses on available treatment options for patients with progressive CRPC and highlights promising treatments that are currently under investigation in clinical trials including abiraterone acetate and MDV3100...
  16. doi request reprint [Nephron-sparing surgery 2012]
    M Janssen
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Aktuelle Urol 43:399-402. 2012
    ..Therefore, whenever feasible, a renal mass should be considered for nephron-sparing surgery...
  17. doi request reprint Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma
    E Herrmann
    Department of Urology, University of Munster, Albert Schweitzer Strasse 33, 48149 Munster, Germany
    World J Urol 29:361-6. 2011
    ..To investigate whether patients with metastatic renal cell carcinoma benefit from sequential therapies with the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib...
  18. doi request reprint [Radical prostatectomy. Detection and management of intra- and postoperative complications]
    M Saar
    Klink für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrberger Straße 1, Geb 6, 66421, Homburg Saar, Deutschland
    Urologe A 53:976-83. 2014
    ..Herein, different scenarios for peri- and postoperative complications are described, and recommendations for best practice solutions are reviewed. ..
  19. doi request reprint [Current developments in the diagnostics and therapy of bladder carcinoma]
    J Kamradt
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstrasse 1, Gebäude 6, Homburg Saar, Germany
    Urologe A 50:179-83. 2011
    ..Furthermore, molecular markers are gaining importance and in the future can be used for identifying patients who may benefit from systemic chemotherapy of bladder carcinoma...
  20. doi request reprint Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy
    M Johannsen
    Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Ann Oncol 22:657-63. 2011
    ....
  21. doi request reprint [Follow-up of urological tumor treatment]
    C H Ohlmann
    Klinik für Urologie und Kinderurologie, Universitatsklinikum des Saarlandes, Kirrbergerstraße, 66421, Homburg Saar, Deutschland
    Urologe A 54:1223-33. 2015
    ..This article therefore gives an overview on current recommendations and evidence for the follow-up of the most important genitourinary tumor types. ..